Skip to main content

Cellectar Biosciences, Inc.

corporate_fare Company Profile

Cellectar Biosciences, Inc.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed CLRB - Latest Insights

CLRB
Apr 21, 2026, 10:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Cellectar Biosciences' Iopofosine I 131 Efficacy Data Accepted for ASCO Presentation
Sentiment: Positive
View Wiseek Article
CLRB
Apr 14, 2026, 8:35 AM EDT
Source: GlobeNewswire
Importance Score:
7
Cellectar Biosciences Initiates Phase 1b Trial for CLR 125 in Triple Negative Breast Cancer
Sentiment: Positive
View Wiseek Article
CLRB
Mar 04, 2026, 7:21 AM EST
Filing Type: 10-K
Importance Score:
9
Cellectar Biosciences Discloses Going Concern Doubt, Financial Restatement, and Heavy Dilution Amidst Clinical Progress
Sentiment: Negative
View Wiseek Article
CLRB
Mar 04, 2026, 7:16 AM EST
Source: Dow Jones Newswires
Importance Score:
9
Cellectar Biosciences Reports $8.35 Loss Per Share for 2025
Sentiment: Negative
View Wiseek Article